Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information

Featured Activity

This activity will review the latest PK recommendations for Factor VIII and IX replacement and how to use and interpret PK parameters to assess treatment plans.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Examining Sterile Compounding for Health-Systems: A Look Ahead to 2020

A Breakfast Symposium to be Conducted at the 2019 ASHP Midyear Clinical Meeting & Exhibition

Monday, December 9, 2018, 6:30 AM - 8:00 AM PT
Mandalay Bay North Convention Center, South Pacific Ballroom E


 

Register to attend in Las Vegas 
 

Register to attend via Webinar 
 

Activity Description

With the effective date of USP Chapters <797> and <800> on December 1, health-systems continue to have questions about practical implementation and compliance measurement techniques. Data has suggested that 100% compliance to USP <797> standards may not be achieved until 2023. This activity seeks to address lingering questions on implementation and approaches to ensure both patient and healthcare worker safety is enforced, and sterility is maintained. A discussion surrounding the finalized updates to both USP chapters will ensure learners are up to date on necessary compliance elements for their health-systems. Pharmacists will be provided background on regulatory requirements for 503A and 503B facilities to assist with decision-making between internal compounding versus outsourced compounded sterile products. Methods to identify and train staff to maintain USP <797> and <800> compliance will be shared. Additional environmental testing and monitoring strategies will be discussed to maintain safety and regulatory compliance.

Learning Objectives

The target audience for this activity includes health‐system pharmacists, including chief pharmacy officers and pharmacy directors. At the completion of this activity, the participant will be better able to:

  • Discuss the finalized updates to USP <797> and USP <800> and the impact on sterile IV compounding safety.
  • Differentiate between 503A and 503B outsourcing facility requirements for compounded sterile preparations.
  • Identify methods for staff education and training for USP <797> and USP <800> compliance.
  • Outline environmental testing and monitoring strategies to ensure compliance with safe sterile and hazardous compounding regulations.

Agenda

6:00 AM Registration and Breakfast
6:30 AM – 8:00 AM CE Activity
Pre-registration is encouraged, and will be used for planning purposes. Seating will be available on a first-come, first-served basis. On-site registration will be available, space permitting.

Faculty

Louis S. Diorio, RPh, FAPhA
Principal
LDT Health Solutions, Inc.
Wayne, New Jersey

Kevin Hansen, PharmD, MS, BCPS
Assistant Director of Pharmacy
Moses H. Cone Memorial Hospital
Greensboro, North Carolina

Fred Massoomi, PharmD, FASHP
Senior Director of Health-System & Hospital Services
Visante, Inc.
Omaha, Nebraska

CE Accreditation

Pharmacists

ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-19-501-L07-P has been assigned to this live knowledge-based activity (initial release date 12-09-19). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Faculty disclosures will be announced prior to the start of the activity. A portion of grant funds received by ProCE from PharMEDium Services, LLC will be used to compensate the faculty for this presentation.

Funding

This activity is provided by ProCE, Inc. and is supported by an educational grant from PharMEDium Services, LLC.

    

Register to attend in Las Vegas 
 

Register to attend via Webinar 
 

Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.